Alessandra Merlini (@merlini_ale) 's Twitter Profile
Alessandra Merlini

@merlini_ale

Medical Oncologist at the University of Turin - Sarcoma Research @SarcomaUniTo

ID: 1066918386

calendar_today06-01-2013 23:00:59

87 Tweet

223 Followers

309 Following

Siyer Roohani (@siyerroohani) 's Twitter Profile Photo

Very pleasant and productive meeting of #EORTC #SoftTissueandBoneSarcomaGroup in the beautiful city of Lugano. - Exciting projects 🔬 - Fascinating exchange with experts in the #Sarcoma field Alessandro Gronchi Dario Callegaro Piotr Rutkowski Lorenzo D'Ambrosio WinetteVanDerGraaf and many others!

Very pleasant and productive meeting of #EORTC #SoftTissueandBoneSarcomaGroup in the beautiful city of Lugano.

- Exciting projects 🔬
- Fascinating exchange with experts in the #Sarcoma field

<a href="/alegronchi/">Alessandro Gronchi</a> <a href="/DCalleMD/">Dario Callegaro</a> <a href="/rutkowskip1972/">Piotr Rutkowski</a> <a href="/DAmbrosio_MD/">Lorenzo D'Ambrosio</a>
<a href="/Winette_vdGraaf/">WinetteVanDerGraaf</a> and many others!
Alessandra Merlini (@merlini_ale) 's Twitter Profile Photo

A pleasure and a privilege to contribute to the cell therapy session with Ignazio Caruana and Dario Sangiolo 🙏 a huge thanks also to the discussants Elena Palassini, Virginia Ferraresi, Valentina , Marcella Tazzari

Alessandra Merlini (@merlini_ale) 's Twitter Profile Photo

Beautiful concert yesterday at #TeatroIvoChiesa. Grateful for the precious support of #SofiaNelCuore to foster #angiosarcoma research within Italian Sarcoma Group and improve our knowledge of the disease 🙏

Beautiful concert yesterday at #TeatroIvoChiesa. Grateful for the precious support of #SofiaNelCuore to foster #angiosarcoma research within <a href="/ItaSarcomaGroup/">Italian Sarcoma Group</a> and improve our knowledge of the disease 🙏
Myriam Chalabi (@myriamchalabi) 's Twitter Profile Photo

Ecstatic and proud to share the NICHE-2 results, now published in NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. John Haanen nej.md/3Ku4X0H

Ecstatic and proud to share the NICHE-2 results, now published in <a href="/NEJM/">NEJM</a>. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. <a href="/HaanenJohn/">John Haanen</a> 
nej.md/3Ku4X0H
Italian Sarcoma Group (@itasarcomagroup) 's Twitter Profile Photo

Crizotinib now available for adult Italian ALK + IMT patients under law 648/96! Thrilled to share this with our community! Thanks to all clinicians and patients who made this possible! 👉tinyurl.com/7zjbecw4 🎗️ #Sarcoma #SarcomaAwarenessMonth

Alessandra Merlini (@merlini_ale) 's Twitter Profile Photo

Had the privilege to attend the 2nd RHU Condor symposium on sarcoma TME and immunotherapy in Bordeaux last week - joining forces/sharing ideas to address one of the most challenging topics in sarcoma research. So grateful to the organizers & colleagues for this opportunity!

Had the privilege to attend the 2nd <a href="/RHUCondor/">RHU Condor</a> symposium on sarcoma TME and immunotherapy in Bordeaux last week - joining forces/sharing ideas to address one of the most challenging topics in sarcoma research. So grateful to the organizers &amp; colleagues for this opportunity!
Andrea Napolitano (@anapolitano_md) 's Twitter Profile Photo

#EORTCSTBSG meeting kicking off in beautiful Turin with Paul's talk on translational research within the context of EORTC studies!

#EORTCSTBSG meeting kicking off in beautiful Turin with Paul's talk on translational research within the context of EORTC studies!
Patrick Schöffski (@schoffski) 's Twitter Profile Photo

Some surprising Brightline-1 figures: only 1 STS subtype included; incidence only 1/330.000/year; only inoperable or metastatic 1st line patients eligible; trial open for accrual for only 752 days ….but: 455 patients screened and 400 patients randomized. YES WE CAN, SARCOMA!

Some surprising Brightline-1 figures: only 1 STS subtype included; incidence only 1/330.000/year; only inoperable or metastatic 1st line patients eligible; trial open for accrual for only 752 days ….but: 455 patients screened and 400 patients randomized. YES WE CAN, SARCOMA!
Lorenzo D'Ambrosio (@dambrosio_md) 's Twitter Profile Photo

Great #CTOS 2024 Annual Meeting in San Diego! Always a unique time for ideas exchange and meeting new and old friends from all around the world. Looking forward for future steps in #sarcoma research! #PUSH Alessandra Merlini Silvia Stacchiotti William Tap Tom Wei-Wu Chen Herbert Loong, MBBS, FASCO Alessandro Gronchi

Great #CTOS 2024 Annual Meeting in San Diego!
Always a unique time for ideas exchange and meeting new and old friends from all around the world.
Looking forward for future steps in #sarcoma research!
#PUSH 
<a href="/merlini_ale/">Alessandra Merlini</a> <a href="/SilviaStacchia/">Silvia Stacchiotti</a> <a href="/WTapMD/">William Tap</a> <a href="/saxotomy/">Tom Wei-Wu Chen</a> <a href="/herbloong/">Herbert Loong, MBBS, FASCO</a> <a href="/alegronchi/">Alessandro Gronchi</a>